Quest Diagnostics Incorporated (NYSE:DGX – Free Report) – Zacks Research dropped their Q4 2026 earnings estimates for Quest Diagnostics in a report released on Wednesday, September 9th. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $2.70 for the quarter, down from their prior estimate of $2.71. The consensus estimate for Quest Diagnostics’ current full-year earnings is $11.15 per share. Zacks Research also issued estimates for Quest Diagnostics’ Q4 2027 earnings at $2.91 EPS.
Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business posted $2.62 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS.
Read Our Latest Stock Analysis on DGX
Quest Diagnostics Stock Down 1.8%
Shares of DGX stock opened at $231.15 on Friday. The stock’s 50-day simple moving average is $229.32 and its 200-day simple moving average is $209.20. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a market capitalization of $25.51 billion, a PE ratio of 24.54, a P/E/G ratio of 2.15 and a beta of 0.55. Quest Diagnostics has a fifty-two week low of $171.18 and a fifty-two week high of $247.19.
Hedge Funds Weigh In On Quest Diagnostics
A number of hedge funds have recently made changes to their positions in DGX. California State Teachers Retirement System lifted its holdings in Quest Diagnostics by 22,733.0% in the 2nd quarter. California State Teachers Retirement System now owns 37,043,773 shares of the medical research company’s stock valued at $7,851,428,000 after purchasing an additional 36,881,535 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Quest Diagnostics in the second quarter valued at about $1,965,923,000. Bank of America Corp DE acquired a new stake in shares of Quest Diagnostics in the second quarter valued at about $410,151,000. Norges Bank purchased a new position in shares of Quest Diagnostics in the fourth quarter worth about $229,522,000. Finally, Boston Partners boosted its position in Quest Diagnostics by 32.8% during the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after acquiring an additional 997,033 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.
Insider Buying and Selling at Quest Diagnostics
In other Quest Diagnostics news, SVP Michael Prevoznik sold 22,677 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the transaction, the senior vice president owned 37,557 shares in the company, valued at approximately $9,130,482.27. This represents a 37.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. Davis sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total value of $2,427,200.00. Following the transaction, the chief executive officer owned 122,423 shares in the company, valued at $29,714,510.56. This represents a 7.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 34,277 shares of company stock valued at $8,316,493. Corporate insiders own 0.88% of the company’s stock.
Quest Diagnostics Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s payout ratio is 36.52%.
About Quest Diagnostics
Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers.
Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments.
Featured Stories
- Five stocks we like better than Quest Diagnostics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
